Envafolimab

Envafolimab is an anti-PD-L1 nanobody used in cancer immunotherapy. It has been approved in China for the treatment of microsatellite instability-high (MSI-H) or MisMatch Repair deficient (dMMR) solid tumours. Envafolimab (KN035) has obtained the U.S. FDA's orphan drug designation for advanced biliary tract cancer.